About DestiNA Genomics
DestiNA Genomics is a company based in Edinburgh (United Kingdom) founded in 2010 by Hugh Ilyine and Juan Jose Diaz Mochon. DestiNA Genomics has raised $1.9 million across 11 funding rounds from investors including European Union. DestiNA Genomics offers products and services including Assay Kits, LiverAce, ChemiRNA Tech, and Custom PNA synthesis. DestiNA Genomics operates in a competitive market with competitors including NuProbe, Nanosphere, ATDBio, Marker Gene Technologies and LGC Biosearch Technologies, among others.
- Headquarter Edinburgh, United Kingdom
- Founders Hugh Ilyine, Juan Jose Diaz Mochon
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Destina Genomics Ltd
- Date of Incorporation 28 Apr, 2010
- Jurisdiction EDINBURGH
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$1.9 M (USD)
in 11 rounds
-
Latest Funding Round
$248.7 K (USD), Grant
Nov 01, 2022
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of DestiNA Genomics
DestiNA Genomics offers a comprehensive portfolio of products and services, including Assay Kits, LiverAce, ChemiRNA Tech, and Custom PNA synthesis.
Kits for nucleic acid testing and RNA detection in research.
Kit for detecting liver injury through miRNA profiling.
Method for direct quantification of miRNAs from body fluids.
Custom design and supply of peptide nucleic acids for clients.
Funding Insights of DestiNA Genomics
DestiNA Genomics has successfully raised a total of $1.9M across 11 strategic funding rounds. The most recent funding activity was a Grant round of $248.7 thousand completed in November 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in DestiNA Genomics
DestiNA Genomics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked |
Investor details for DestiNA Genomics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by DestiNA Genomics
Investment portfolio details for DestiNA Genomics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - DestiNA Genomics
Detailed financials for DestiNA Genomics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Destina Genomics Comparisons
Peer comparison for DestiNA Genomics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of DestiNA Genomics
DestiNA Genomics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as NuProbe, Nanosphere, ATDBio, Marker Gene Technologies and LGC Biosearch Technologies, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Sensitive multiplex platforms for QPCR are developed using toehold probes.
|
|
| Locked | Locked | Locked |
Diagnostic tests for personalized medicine targeting infections are provided.
|
|
| Locked | Locked | Locked |
Developer of oligonucleotides
|
|
| Locked | Locked | Locked |
Develops kits and reagents for research application
|
|
| Locked | Locked | Locked |
Provider of genomic analysis tools, instrumentation and services
|
Detailed competitors of DestiNA Genomics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Destina Genomics
Complete news archive for DestiNA Genomics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about DestiNA Genomics
DestiNA Genomics was founded in 2010.
DestiNA Genomics is headquartered in Edinburgh, United Kingdom. It is registered at Edinburgh, Scotland, United Kingdom.
Hugh Ilyine is the current CEO of DestiNA Genomics. They have also founded this company.
DestiNA Genomics is a funded company, having raised a total of $1.9M across 11 funding rounds to date.
DestiNA Genomics was founded in 2010 in Edinburgh, United Kingdom, within the genomics sector. Non-enzymatic detection technology is created through dynamic chemistry, featuring DGL probes that integrate aldehyde-modified nucleobases with peptide nucleic acid. Binding to target sequences is facilitated, leaving blanks at deletion or mutation sites to minimize false positives over enzymatic methods. Applications cover insertions, deletions, mutations, and non-mutated nucleic acid sequences.
DestiNA Genomics's top competitors include NuProbe, Nanosphere and ATDBio.
DestiNA Genomics offers Assay Kits, LiverAce, ChemiRNA Tech, and Custom PNA synthesis.
DestiNA Genomics has 1 investor. Key investors include European Union.